Palatin Technologies, in partnership with King Pharmaceuticals, is in middle-stage trials (Phase II of a total of three) to research another nasal-sprayed chemical, PT-141, which stimulates the hypothalamus' melanocortin receptors, which are responsible for hunger and may have a more potent arousal effect.